Merck & Co. is paying $10.8 billion to buy Prometheus Biosciences for its late-phase bowel disease drug candidate. Months after midphase data sent Prometheus’ stock spiraling upward, Merck has agreed ...
The Central Intelligence Agency’s venture investment arm, IQT, has invested in AI data center company Prometheus Hyperscale, which is developing campuses in Wyoming and Texas, the company said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results